Arsenic Trioxide in Treating Young Patients With Refractory Leukemia or Lymphoma

Completed · Phase 1

Conditions studied: Leukemia, Lymphoma

In brief

RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of arsenic trioxide in treating young patients with leukemia or lymphoma.

Key facts

Study ID
NCT00020111
Run by
National Cancer Institute (NCI)
Starts
2000-03-01
Last updated by the study team
2015-04-29

Who can join

Age: 2 and older, up to 21. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.